Antiobesity Drug Discovery Research: In vitro Models for Shortening the Drug Discovery Pipeline

被引:1
|
作者
Radheshyam [1 ]
Gauniya, Priyanka [1 ]
Semalty, Mona [1 ]
Semalty, Ajay [1 ]
机构
[1] Hemwati Nandan Bahuguna Garhwal Univ, Dept Pharmaceut Sci, Cent Univ, Srinagar, Uttarakhand, India
关键词
Pancreatic lipase inhibition; obesity and overweight; BMI; cell lines; preclinical tests; weight management; antiobesity drugs; ADIPOSE-TISSUE; INHIBITS ADIPOGENESIS; GENE-EXPRESSION; C3H10T1/2; CELLS; OBESITY; ADIPOCYTE; DIFFERENTIATION; LIPASE; LINE; DIET;
D O I
10.2174/0113894501289136240312060838
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Obesity is a growing global health problem, leading to various chronic diseases. Despite standard treatment options, the prevalence of obesity continues to rise, emphasizing the need for new drugs. in vitro methods of drug discovery research provide a time and cost-saving platform to identify new antiobesity drugs. The review covers various aspects of obesity and drug discovery research using in vitro models. Besides discussing causes, diagnosis, prevention, and treatment, the review focuses on the advantages and limitations of in vitro studies and exhaustively covers models based on enzymes and cell lines from different animal species and humans. In contrast to conventional in vivo animal investigations, in vitro preclinical tests using enzyme- and cell line-based assays provide several advantages in development of antiobesity drugs. These methods are quick, affordable, and provide high-throughput screening. They can also yield insightful information about drug-target interactions, modes of action, and toxicity profiles. By shedding light on the factors that lead to obesity, in vitro tests can also present a chance for personalized therapy. Technology will continue to evolve, leading to the creation of more precise and trustworthy in vitro assays, which will become more and more crucial in the search for novel antiobesity medications.
引用
收藏
页码:388 / 403
页数:16
相关论文
共 50 条
  • [1] Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease
    Jonathan Cechetto
    Hee Kyoung Jeon
    Jiyeon Jang
    Doyoon Kwon
    Thierry Christophe
    Priscille Brodin
    Gyongseon Yang
    Jair Neto
    Lucio Freitas Junior
    BMC Proceedings, 5 (Suppl 1)
  • [2] Concept of Drug Metabolism in Drug Discovery Pipeline
    Ahmad, Syed Sayeed
    Kamal, Mohammad A.
    CURRENT DRUG METABOLISM, 2019, 20 (09) : 697 - 700
  • [3] Translational in vitro research: integrating 3D drug discovery and development processes into the drug development pipeline
    Kelm, Jens M.
    Lal-Nag, Madhu
    Sittampalam, Gurusingham Sitta
    Ferrer, Marc
    DRUG DISCOVERY TODAY, 2019, 24 (01) : 26 - 30
  • [4] Animal models in the drug discovery pipeline for Alzheimer's disease
    Van Dam, Debby
    De Deyn, Peter Paul
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 (04) : 1285 - 1300
  • [5] FASTDock: A Pipeline for Allosteric Drug Discovery
    Ahmed, Furyal
    Brooks III, Charles L.
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 63 (22) : 7219 - 7227
  • [6] DRUG DISCOVERY Priming the antimalarial pipeline
    Fidock, David A.
    NATURE, 2010, 465 (7296) : 297 - 298
  • [7] THE APPLICATION OF IN-VITRO MODELS OF DRUG-METABOLISM AND TOXICITY IN DRUG DISCOVERY AND DRUG DEVELOPMENT
    BALL, SE
    SCATINA, JA
    SISENWINE, SF
    FISHER, GL
    DRUG AND CHEMICAL TOXICOLOGY, 1995, 18 (01) : 1 - 28
  • [8] The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
    Mdluli, Khisimuzi
    Kaneko, Takushi
    Upton, Anna
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2015, 5 (06):
  • [9] Minipigs as models in drug discovery
    Singh, Vijay K.
    Thrall, Karla D.
    Hauer-Jensen, Martin
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (12) : 1131 - 1134
  • [10] DEVELOPMENT OF PHENOTYPICAL IN VITRO MODELS IN PAIN FOR EARLY DRUG DISCOVERY
    Martinez, A. L.
    Brea, J.
    Burgueno, J.
    Merlos, M.
    Monroy, X.
    Vela, J. M.
    Cadavid, M., I
    Loza, M., I
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 16 - 17